|
MONTREAL, QUEBEC and MISSISSAUGA, ONTARIO--(Marketwired - June 17, 2013) - Paladin Labs Inc. (TSX:PLB), a leading specialty pharmaceutical company and Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced that they have amended their loan arrangements (the "Loan") originally agreed to in May 2012. In May of 2012, Nuvo drew down the first $4.0 million tranche of the Loan which has been paid down to its current principle balance of $2.0 million. |
